The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: A multinational perspective

Journal of Rheumatology

Volumn 30, Issue 10, 2003, Pages 2234-2240

  Mockenhaupt, Maja ^b   Kelly, Judith Parsells ^b   Kaufman, David ^b   Stern, Robert S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Case control study; Nonsteroidal antiinflammatory drugs multivariate analysis; Stevens Johnson syndrome

Indexed keywords

ACEMETACIN; ALLOPURINOL; AMOXICILLIN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; BENZYDAMINE; CARBAMAZEPINE; DICLOFENAC; DIFLUNISAL; ETODOLAC; FENTIAZAC; FEPRAZONE; FLUPIRTINE; IBUPROFEN; INDOBUFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MECLOFENAMIC ACID; MEFENAMIC ACID; NIFLUMIC ACID; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PHENYLBUTAZONE; PIROXICAM; PROPIONIC ACID DERIVATIVE; SULINDAC; TENOXICAM; UNINDEXED DRUG;

ARTHRITIS; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG INDUCED DISEASE; FOOD AND DRUG ADMINISTRATION; GERMANY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; GERMANY; HUMANS; INTERNATIONAL COOPERATION; MALE; MULTIVARIATE ANALYSIS; RISK FACTORS; STEVENS-JOHNSON SYNDROME; UNITED STATES;

EID: 0141865721     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Stern RS, Bigby M. An expanded profile of cutaneous reactions to nonsteroidal anti-inflammatory drugs. JAMA 1984;252:1433-7.
2. Bigby M, Stern RS. Cutaneous reactions to nonsteroidal anti-inflammatory drugs. J Am Acad Dermatol 1985;12:866-76.
3. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Fléchet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France 1981-1985. Arch Dermatol 1990;126:37-42.
4. Schopf E, Stühmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome: An epidemiologic study from West Germany. Arch Dermatol 1991;127:839-42.
5. Stern RS, Chan H-L. Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis. J Am Acad Dermatol 1989;21:317-22.
6. Strom BL, Carson JL, Halpern AC, et al. A population-based study of Stevens-Johnson syndrome: incidence and antecedent drug exposures. Arch Dermatol 1991;127:831-8.
7. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85.
8. Chan LC, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Arch Dermatol 1990;126:43-7.
9. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.
10. Bastuji-Garin S, Rzany B, Stern RS, Shear N, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis. Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-6.
11. Kelly JP, Auquier A, Rzany B, et al. An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods. J Clin Epidemiol 1995;48:1099-108.
12. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): Structure and results of a population-based registry. J Clin Epidemiol 1996;49:769-73.
13. Schwabe U, Paffrath D. Arzneiverordnungsreport 1992-2000. Stuttgart: Gustav Fischer Verlag; 2000.
14. Food and Drug Administration. FDA Spontaneous Reporting System: Adverse reactions reported to FDA from 1969 thru October 1997. Washington, DC: Department of Health and Human Services; 1998.
15. Woodwell DA. National Ambulatory Medical Care Survey: 1997 Summary. Adv Data 1999;305:1-28.
16. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. New York: Van Nostrand Reinhold; 1982.
17. Stata reference manual, Release 6. College Station, TX: Stata Corp.; 1999.
18. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Lancet 1999;353:2190-4.
19. Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastrgenterol 2001;96:1019-27.
20. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS Study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
21. Kromann-Andersen H, Pedersen A. Reported adverse reactions to and consumption of nonsteroidal anti-inflammatory drugs in Denmark over a 17-year period. Dan Med Bull 1988;35:187-92.